COPD Exacerbation Costs in the IMPACT Study: A Within-Trial Analysis
May 6th 2020Treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) compared with FF/VI or UMEC/VI reduced exacerbation-related costs associated with chronic obstructive pulmonary disease (COPD) in the US healthcare system.